A modern approach to the early diagnosis of prostate cancer

Prostate cancer is a formidable disease, which is one of the most common types of cancer in men. This disease is characteristic of the elderly, however, like many other diseases, in recent years this pathology has been "getting younger" and increasingly begins to occur at an earlier age. It is worth noting that prostate cancer is one of the "leading" five causes of death among older men. 

Unfortunately, the situation in our country is not the best with the early diagnosis of this pathology. This is due to the fact that in the early stages the disease may be asymptomatic, or manifest itself with such nonspecific symptoms as:

Difficulty urinating

Frequent urination

Urinary incontinence

Frequent urge to urinate

And our mentality, unfortunately, is such that people seek specialized medical care only when obvious symptoms appear, from which the quality of life begins to suffer. And very wrongly, because statistics are relentless! Prostate cancer is the cause of almost 10% of cancer deaths in men and is one of the main causes of death in older men. In men over the age of 60, this is the most common malignant neoplasm. In the period from 1999 to 2009, the incidence of prostate cancer increased 2.8 times (the first place among malignant neoplasms)

It is worth noting that in developed countries, men after the age of 45 are regularly tested for early diagnosis of prostate cancer.

For an accurate diagnosis of a prostate tumor, a biopsy is mandatory. The indication for the appointment of this diagnostic method is an increase in the blood level of a substance such as prostate-specific antigen (PSA), which is considered a marker of prostate cancer. However, a biopsy is not an easy procedure, among the complications of which there are: the spread of infection, hemorrhage into the urethra or bladder. At the same time, it was found that 75% of biopsies have a negative result, that is, in ¾ of cases, the appointment of this procedure turned out to be unjustified. This is due to the fact that PSA has a low diagnostic specificity, and it should be borne in mind that an increase in PSA levels can occur not only in malignant tumors, but also in other pathologies of the prostate gland. In this regard, there is a need to prescribe a more specific study, which will in many cases exclude the appointment of a biopsy.
Such a study is the determination of the prostate health Index (PHI). The Prostate Health Index is a multifactorial calculated indicator that evaluates the risk of prostate tumor diseases based on several indicators, such as total and free PSA and -2 proPSA, which are various forms of prostate-specific antigen found in the body.

The prostate health Index is the most specific indicator for assessing the presence of a prostate tumor, which avoids the "unnecessary" appointment of a prostate biopsy, while not missing malignant tumors!

The OLYMP branches of independent laboratories make the determination of the prostate health index using modern high-precision analyzers that negate the probability of error and allow for the highest diagnostic accuracy.

You can contact any of the 180 treatment rooms of the OLYMP CDL through Kazakhstan in order to determine the prostate health index, a specific indicator that allows you to avoid unjustified biopsy appointment and diagnose prostate cancer in time.